Core Insights - Pfizer has raised and tightened its full-year earnings guidance for the second consecutive quarter, driven by strong demand for its Eliquis blood thinner and a recovery in cardiovascular therapies [1][2] - The company increased its annual diluted EPS range to $3.00 to $3.15 from $2.90 to $3.10, while reaffirming full-year revenue expectations of $61 billion to $64 billion [1] Financial Performance - Adjusted EPS for the third quarter was $0.87, exceeding expectations of $0.63, with revenue of $16.65 billion, also surpassing the forecast of $16.59 billion [2] - Eliquis sales increased by 22% to $2.02 billion, supported by higher demand for heart disease medications [2] Strategic Developments - The company is actively cutting costs and launching new products while managing litigation related to Metsera, including lawsuits concerning Novo Nordisk's unsolicited bid following Pfizer's previous $7.3 billion agreement [2] - Pfizer's agreement with the U.S. administration to lower Medicare drug prices in exchange for three years of tariff relief is expected to provide greater policy visibility [2]

Market Overview - U.S. equities faced a significant downturn on November 4, 2025, with all three major indexes closing in the red, particularly the tech-heavy Nasdaq Composite, which led the declines [1][2] - The S&P 500 fell 1.2% to 6,771 points, while the Dow Jones Industrial Average decreased by 0.5% or approximately 238 points to 47,085, and the Nasdaq Composite dropped 2% to 23,348 [2] - The Cboe Volatility Index (VIX) surged 10% to 18.9, indicating increased investor apprehension amid concerns over valuations and a potential market correction [2] Economic Data and Events - The ongoing U.S. government shutdown is delaying key economic data releases, increasing focus on private sector data [3] - The ADP employment report is anticipated, which may provide insights into hiring trends following a dip in September [3] - The ISM Manufacturing PMI declined to 48.7 in October from 49.1 in September, marking the eighth consecutive month of contraction [4] Corporate Developments - Palantir Technologies (PLTR) saw a significant decline of 7.9% despite surpassing analysts' forecasts for sales and profit, raising concerns over high valuations [5] - Nvidia (NVDA) fell 4%, and Microsoft (MSFT) dipped 1%, reflecting growing concerns about the sustainability of the AI rally [5] - Uber Technologies (UBER) slumped 6.3% despite reporting better-than-expected financial results [5] - Yum! Brands (YUM) rose 6.1% after announcing strong quarterly results and considering selling its Pizza Hut unit [5] - Kinross Gold Corporation (KGC) reported robust third-quarter results, including record free cash flow and an increase in share buyback target and dividend [6] Earnings Announcements - Advanced Micro Devices, Inc. (AMD) is expected to report a 27.63% year-over-year increase in earnings per share [10] - Arista Networks, Inc. (ANET) is forecasted to see a 14.04% increase in earnings per share [10] - Axon Enterprise, Inc. (AXON) plunged 20% in after-hours trading following a Q3 earnings miss [10] - Digital Turbine (APPS) surged 22% in after-hours trading after reporting its FY 2026 Q2 earnings [10]

The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more and more heated. ...

Core Insights - Pfizer is suing Metsera Inc to block a takeover by Novo Nordisk, indicating a fierce competition in the obesity drug market [1][3] - Novo Nordisk has increased its bid for Metsera to $86.20 per share, valuing the company at approximately $10 billion, while Pfizer's offer is around $70 per share [3] - Viking Global, a hedge fund led by Andreas Halvorsen, holds a significant position in Metsera, having initially invested at an average price of $27.22, which has now more than doubled [4][6] Company Actions - Pfizer's lawsuit is described as a reaction to Novo Nordisk's aggressive bid, highlighting the stakes involved in the obesity treatment sector [3][6] - Novo Nordisk's bid includes a contingent value right of up to $24 in cash, showcasing its commitment to acquiring Metsera [3] Market Dynamics - The competition between Pfizer and Novo Nordisk reflects the high stakes in the obesity drug market, particularly in light of the success of Novo's products like Ozempic and Wegovy [3][6] - Viking Global's strategic position in Metsera suggests that hedge funds are capitalizing on the ongoing battle between the pharmaceutical giants [4][6]

Adding more drama to Metsera Inc.’s (NASDAQ:MTSR) acquisition deal, Novo Nordisk A/S (NYSE:NVO) increased the deal proposal to $62.20 per share in cash, up from $56.50. • Watch the MTSR momentum here.Metsera said the amended proposal constitutes a “Superior Company Proposal.”Additionally, Metsera would issue Novo Nordisk non-voting preferred stock representing 50% of Metsera’s share capital.On the same day, Metsera would declare a dividend of $62.20 per share in cash (up from $56.50).Metsera shareholders co ...

Skip to Main Content Skip to Search This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. Novo Nordisk Is Still Beating Pfizer in Battle Over Metsera By Josh Nathan-Kazis Updated Nov 04, 2025, 1:35 pm EST / Original Nov 04, 2025, 12:26 pm EST Share Resize Reprints VKTX Buying ...

Core Viewpoint - Pfizer's stock has declined nearly 60% since the end of 2021, despite third-quarter financial results exceeding expectations, primarily due to underperformance in key growth products [2][5][7]. Financial Performance - Adjusted diluted earnings were $0.87 per share, surpassing the consensus estimate of $0.63 per share [3]. - Revenue reached $16.7 billion, slightly above the expected $16.5 billion [3]. - The revenue increase was largely driven by older products, while cost reductions and lower tax liabilities contributed positively to the bottom line [3][7]. Product Performance - Sales of Eliquis, a blood thinner, amounted to $2 billion, up 22% year-over-year, exceeding the $1.8 billion consensus estimate [9]. - Sales of Paxlovid, the Covid-19 antiviral, were $1.2 billion, down 55% from the previous year, while Comirnaty, the Covid-19 vaccine, also saw a 20% decline in sales [11]. - Sales of Padcev and Adcetris, cancer treatments acquired from Seagen, were $464 million and $215 million respectively, both falling short of Wall Street expectations [12]. Strategic Outlook - Pfizer maintained its full-year revenue forecast but narrowed its earnings estimate to between $3 and $3.15 per share, up from a previous range of $2.90 to $3.10 [13]. - The company is facing challenges as key products approach patent expirations, and the market for Covid-19 products has contracted [5][7]. - Ongoing legal issues regarding the acquisition of Mestera have added uncertainty to Pfizer's strategic positioning in the obesity market [14].

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team operates from key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Expertise and Focus Areas - The company specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive delivers news and insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

We got an oldfashioned bidding war going on between Nova Nordisk and Fizer to take control of Metsera. Our viewers may remember it was last week or actually a few weeks ago Fizer had a deal to acquire this company to try to build its presence uh in the GLP1 arena essentially uh reducing obviously people's uh weight um where it really has not had a great deal of success going up against the incumbents Eli Liy and Nova Nordis. But then Novo came in last week with an interesting offer in terms of its structure ...

Core Insights - Pfizer reported third-quarter 2025 adjusted earnings per share (EPS) of 87 cents, exceeding the Zacks Consensus Estimate of 66 cents, but reflecting an 18% decline year over year [1] - Total revenues were $16.7 billion, down 6% from the previous year, primarily due to decreased sales from COVID-19 products, Comirnaty and Paxlovid, although it slightly beat the Zacks Consensus Estimate of $16.60 billion [2] Revenue Breakdown - International revenues increased by 2% on an operational basis to $5.96 billion, while U.S. revenues fell by 11% to $10.69 billion [2] - The Primary Care segment saw a 16% operational decline to $7.65 billion, while Specialty Care recorded a 1% increase to $4.41 billion, and Oncology sales rose by 4% to $4.25 billion [3] Product Performance - Eliquis sales rose by 22% to $2.02 billion, surpassing estimates, despite some price erosion in international markets [4] - Global Prevnar family revenues decreased by 4% to $1.74 billion, missing estimates, with U.S. sales down 12% but international sales up 17% [5] - Comirnaty sales were $1.15 billion, down 20% year over year, but still beat estimates [6] - Paxlovid revenues fell by 55% to $1.23 billion due to lower infection rates, although it exceeded estimates [7] - New product Abrysvo recorded sales of $279 million, down 22% year over year due to limited vaccination recommendations [8] Specialty Care and Oncology - Vyndaqel family revenues rose by 7% to $1.59 billion, driven by increased diagnosis and treatment rates, but missed estimates [9][10] - Ibrance revenues declined by 5% to $1.06 billion, beating estimates [11] - Among ADCs from the Seagen acquisition, Adcetris sales fell by 20% to $215 million, while Padcev rose by 13% to $464 million, missing estimates [12] Guidance and Outlook - Pfizer reaffirmed its 2025 revenue guidance of $61.0 billion to $64.0 billion and raised its adjusted EPS guidance to $3.00-$3.15 from $2.90-$3.10 [14] - Research and development expenses are projected to be between $10.0 billion and $11.0 billion, with an adjusted tax rate expected around 11% [15] Competitive Landscape - Pfizer is engaged in a competitive acquisition battle with Novo Nordisk for Metsera, with Pfizer's offer at approximately $4.9 billion and Novo Nordisk's unsolicited proposal at around $6.5 billion [18][19] - Pfizer has also signed a drug pricing agreement with the Trump administration, aiming to cut prescription drug prices in exchange for tariff exemptions [20]